Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Lung Neoplasms 8Carcinoma, Non-Small-Cell Lung 6Pancreatic Neoplasms 5Ovarian Neoplasms 5Colorectal Neoplasms 5Neoplasm Metastasis 4Fallopian Tube Neoplasms 4Multiple Myeloma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Primary Myelofibrosis 2Neoplasms 2Myelodysplastic Syndromes 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Glioblastoma 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1

Interventions

Cyclophosphamide 11ruxolitinib 10fludarabine phosphate 9Tacrolimus 7Filgrastim 7fludarabine 6Decitabine 6Whole-Body Irradiation 5Peripheral Blood Stem Cell Transplantation 5Mycophenolic Acid 5Busulfan 5navitoclax 4Sirolimus 4Etoposide 4Azacitidine 4Specimen Handling 3Methylprednisolone 3Methotrexate 3Melphalan 3Cyclosporine 3Antilymphocyte Serum 3venetoclax 2thymoglobulin 2durvalumab 2Vorinostat 2Thiotepa 2Sunitinib 2Stem Cell Transplantation 2Radiotherapy 2Prednisone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Primary Myelofibrosis × Disulfides × Clear all
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02871323 2019-08-20

Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Northwestern University

Phase 1 Withdrawn
Myeloid

Polycythemia Vera, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡